Cerebellar post-stroke deep brain stimulation appears safe and feasible in a small trial

Aug. 15, 2023
Early NIH-funded trial is first step towards development of a potential stroke treatment.

The results of an early-stage clinical trial indicate that deep brain stimulation (DBS) applied to the cerebellum may help recovery of upper limb function following stroke. The findings, published in Nature Medicine, support the design of larger, blinded clinical trials to fully assess the benefit of such a treatment. This trial, which was conducted at the Cleveland Clinic, Cleveland, is one of the first-in-human tests of post-stroke cerebellar DBS, supported by the National Institutes of Health’s Brain Research through Advancing Innovative Neurotechnologies Initiative, or The BRAIN Initiative. 

Twelve individuals with moderate to severe upper extremity impairment following stroke were enrolled to receive DBS to an area within the cerebellum called the dentate nucleus (DN). Each participant received physical therapy before, during, and after DBS, which was delivered continuously for between four and eight months.

The primary goal of this study was to determine whether cerebellar DBS in combination with physical therapy is a safe and potentially effective treatment for post-stroke motor deficits. No serious adverse events or device failures were reported during the trial. These encouraging results support the design of larger, more rigorous clinical trials aimed at determining how effective DBS plus physical therapy is compared to just physical therapy alone.

The study’s secondary findings were also promising, with nine out of 12 participants showing improvements in motor function following DBS plus physical therapy. These improvements persisted even after DBS was turned off. Importantly, the time that had passed since the stroke occurred did not seem to affect the potential for improvement. Not all improved to the same degree. Participants who retained some level of motor function in the hand experienced clinically significant recovery. However, participants with a low level of motor function in hand showed only minimal benefit. All who had some measure of control showed improvement over the course of the treatment.

NIH release

Photo 89045623 © Natal'ya Buzuevskaya | Dreamstime.com
merovingian/iStock/Getty Images Plus/Getty Image